467 / 1851
EORTC/DAHANCA 29 randomized phase III
LARYNX, PHARYNX*
HPVneg (p16); Stage 3-4 (T2-4,N0-3)
RANDOMIZE
Accl RT
(6 fx/wk)
+cisPl
* Except NPC
+ Nimorazole
(1.2 g/m2)
Accl RT
(6 fx/wk)
+cisPl
Stratify:
Stage
Site
Inst.
Hypox.
Gene
profile
(retro-spective)
640 patients – (>200 with positive hypoxic gene profile).
Pivotal trial to establish the true indication of Nimorazole in
Chemoradiotherapy of advanced HNSCC and the value of the
hypoxic gene profile
Role of Nimorazole in chemo-radiation of HPV neg HNSCC